



CERTIFICATE



This is to certify that

BioNTech SE

An der Goldgrube 12
55131 Mainz
Germany

with the organizational units/sites as listed in the annex

has implemented and maintains an **Occupational Health and Safety Management System.**

Scope:

Research, development and production of immunological and RNA-based pharmaceutical products as well as diagnostic methods

Through an audit, documented in a report, it was verified that the management system fulfills the requirements of the following standard:

ISO 45001 : 2018

Certificate registration no. 31613916 OHS18
Valid from 2024-01-02
Valid until 2027-01-01
Date of certification 2024-01-02



DQS GmbH

Christian Gerling
Managing Director

DQS IS A MEMBER OF





**Annex to certificate
Registration No. 31613916 OHS18**

BioNTech SE

An der Goldgrube 12
55131 Mainz
Germany

Location

Scope

**31619801
BioNTech SE
Munich Small Molecules
Am Klopferspitz 19a
82152 Planegg, Martinsried
Germany**

Research and development of immunological small molecules

**31619803
BioNTech SE
Munich Antibody Platform (MAP)
Forstenrieder Straße 8-14
82061 Neuried b. München
Germany**

Research and development of immunological small molecules

**31619700
reSano GmbH
An der Goldgrube 12
55131 Mainz
Germany**

Research and development of immunological and RNA-based pharmaceutical products

**31619693
BioNTech Diagnostics GmbH
An der Goldgrube 12
55131 Mainz
Germany**

Development of diagnostic methods

**31619694
BioNTech Cell & Gene Therapies GmbH
An der Goldgrube 12
55131 Mainz
Germany**

Research and development of immunological pharmaceutical products as well as diagnostic methods

**31619695
BioNTech Delivery Technologies GmbH
Weinbergweg 23
06120 Halle
Germany**

Development and production of transfection reagents and modified nuclein acids



**Annex to certificate
Registration No. 31613916 OHS18**

BioNTech SE

An der Goldgrube 12
55131 Mainz
Germany

Location

**31619697
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz
Germany**

Scope

Development and manufacturing of immunological and RNA-based pharmaceutical products